Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
Top Cited Papers
Open Access
- 13 April 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (15) , 1567-1577
- https://doi.org/10.1056/nejmoa060900
Abstract
In observational studies, lower homocysteine levels are associated with lower rates of coronary heart disease and stroke. Folic acid and vitamins B6 and B12 lower homocysteine levels. We assessed whether supplementation reduced the risk of major cardiovascular events in patients with vascular disease. We randomly assigned 5522 patients 55 years of age or older who had vascular disease or diabetes to daily treatment either with the combination of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 or with placebo for an average of five years. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, and stroke. Mean plasma homocysteine levels decreased by 2.4 μmol per liter (0.3 mg per liter) in the active-treatment group and increased by 0.8 μmol per liter (0.1 mg per liter) in the placebo group. Primary outcome events occurred in 519 patients (18.8 percent) assigned to active therapy and 547 (19.8 percent) assigned to placebo (relative risk, 0.95; 95 percent confidence interval, 0.84 to 1.07; P=0.41). As compared with placebo, active treatment did not significantly decrease the risk of death from cardiovascular causes (relative risk, 0.96; 95 percent confidence interval, 0.81 to 1.13), myocardial infarction (relative risk, 0.98; 95 percent confidence interval, 0.85 to 1.14), or any of the secondary outcomes. Fewer patients assigned to active treatment than to placebo had a stroke (relative risk, 0.75; 95 percent confidence interval, 0.59 to 0.97). More patients in the active-treatment group were hospitalized for unstable angina (relative risk, 1.24; 95 percent confidence interval, 1.04 to 1.49). Supplements combining folic acid and vitamins B6 and B12 did not reduce the risk of major cardiovascular events in patients with vascular disease. (ClinicalTrials.gov number, NCT00106886; Current Controlled Trials number, ISRCTN14017017.)Keywords
This publication has 18 references indexed in Scilit:
- Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trialsThe American Journal of Clinical Nutrition, 2005
- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysisBMJ, 2002
- MTHFR 677C→T Polymorphism and Risk of Coronary Heart DiseaseJAMA, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic EvidenceAnnals of Internal Medicine, 1999
- Homocyst(e)ine, Diet, and Cardiovascular DiseasesCirculation, 1999
- Homocysteine and AtherothrombosisNew England Journal of Medicine, 1998
- A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakesPublished by American Medical Association (AMA) ,1995
- Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons.Circulation Research, 1983
- HomocystinemiaNew England Journal of Medicine, 1974